Evaluating RMC-6236 for advanced solid tumors with specific RAS mutations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1/1b multicenter open-label study aims to assess the safety, tolerability, pharmacokinetics, and clinical activity of RMC-6236, a RAS-MULTI(ON) inhibitor, in adults with advanced solid tumors that have specific RAS mutations. The study will involve escalating doses of the drug to determine the maximum tolerated dose and/or recommended phase 2 dose. Participants must have previously received standard therapy appropriate for their tumor type and stage, and their tumors must be confirmed to harbor specific KRAS or RAS mutations through DNA sequencing.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).
* Treatment naive or have received prior standard therapy appropriate for tumor type and stage
* Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Adequate organ function

Exclusion Criteria:

* Primary central nervous system (CNS) tumors
* Active, untreated brain metastases
* Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
* History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy

Other inclusion/exclusion criteria may apply.

Where it's running

• UC Irvine/Chao Family Comprehensive Cancer Center
  Orange, California, United States Recruiting
• UCLA
  Santa Monica, California, United States Recruiting
• Moffitt Cancer Center
  Tampa, Florida, United States Recruiting
• Piedmont Healthcare
  Atlanta, Georgia, United States Recruiting
• Mary Bird Perkins Cancer Center
  Baton Rouge, Louisiana, United States Recruiting
• Johns Hopkins University
  Baltimore, Maryland, United States Recruiting

Study contacts

• Study coordinator: Revolution Medicines, Inc.
• Email: medinfo@revmed.com
• Phone: 1-844-273-8633

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BPI-572270 in RAS-mutant advanced solid tumors (including NSCLC, CRC, PDAC)

  This study tests whether BPI-572270 is safe and tolerable in adults with RAS-mutant advanced solid tumors and looks for signs of clinical activity.

  Recruiting Phase 1/2 Betta Pharmaceuticals Co., Ltd. · Blacktown, New South Wales and 6 other locations · NCT07435038

• RMC-5127 for advanced cancers with KRAS G12V mutation

  This trial will test whether the experimental drug RMC-5127, alone or with daraxonrasib or cetuximab, helps adults with advanced KRAS G12V-mutant solid tumors.

  Recruiting at 9 sites Phase 1 Revolution Medicines, Inc. · New Haven, Connecticut and 8 other locations · NCT07349537

• Evaluating RMC-9805 for KRAS G12D-Mutant Solid Tumors

  This study is testing a new drug called RMC-9805 to see if it can safely help adults with solid tumors that have a specific KRAS G12D mutation.

  Recruiting at 17 sites Phase 1 Revolution Medicines, Inc. · Sacramento, California and 16 other locations · NCT06040541

• Combining RAS(ON) inhibitors with ivonescimab for adults with RAS‑mutant advanced solid tumors

  This trial will test whether combining RAS(ON) inhibitors with ivonescimab is safe and can shrink or control tumors in adults with advanced or metastatic solid tumors that have RAS mutations.

  Recruiting at 19 sites Phase 1/2 Revolution Medicines, Inc. · Scottsdale, Arizona and 18 other locations · NCT07397338

• BMS-986523 alone and with other cancer medicines for advanced KRAS-altered solid tumors

  This treatment tests whether BMS-986523, alone or combined with chemotherapy or immunotherapy, helps people with advanced KRAS-altered lung, colorectal, or pancreatic cancers.

  Recruiting at 6 sites Phase 1/2 Bristol-Myers Squibb · Baltimore, Maryland and 7 other locations · NCT07223047

• JYP0015 for adults with advanced RAS‑mutant solid tumors

  This trial tests whether the oral drug JYP0015 is safe and can shrink tumors in adults whose advanced solid cancers have specific RAS mutations.

  Recruiting Phase 2 Guangzhou JOYO Pharma Co., Ltd · Beijing, Beijing Municipality · NCT06895031

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.